Visit https://www.peervoice.com/YZK860 to view the entire programme with slides. After completing “Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.